Cyclacel
Investors & Media

News

All Releases
View Summary Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference
Sep 21, 2017
PDF 13.1 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
Sep 8, 2017
PDF 12.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial ResultsĀ 
Aug 9, 2017
PDF 31.4 KB Add to Briefcase
View Summary Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
Aug 7, 2017
PDF 19.3 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results
Aug 2, 2017
PDF 12.9 KB Add to Briefcase
View Summary Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Jul 21, 2017
PDF 15.0 KB Add to Briefcase
View Summary Cyclacel Announces Pricing of $13.2 Million Underwritten Public Offering
Jul 19, 2017
PDF 14.8 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results
May 11, 2017
PDF 28.2 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results
May 5, 2017
PDF 12.6 KB Add to Briefcase
View Summary Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140
Apr 4, 2017
PDF 16.4 KB Add to Briefcase
View Summary Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
Apr 2, 2017
PDF 17.2 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 28, 2017
PDF 30.1 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results
Mar 21, 2017
PDF 12.6 KB Add to Briefcase
View Summary Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI
Mar 7, 2017
PDF 15.3 KB Add to Briefcase
View Summary Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
Feb 23, 2017
PDF 19.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference
Feb 6, 2017
PDF 12.9 KB Add to Briefcase
View Summary Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia
Dec 1, 2016
PDF 17.1 KB Add to Briefcase
  EORTC-NCI-AACR 2016. Abstract 355: Therapeutic potential of novel PLK1 inhibitor, CYC140, in esophageal cancer and acute leukemia
Dec 1, 2016
PDF 663.7 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results
Nov 14, 2016
PDF 29.2 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results
Nov 7, 2016
PDF 13.3 KB Add to Briefcase
Showing 1-20 of 351 Page: 1 2 3 4 5 ... 18  Next 20
Add to Briefcase = add release to Briefcase
Investors & Media